JAZZ News and Press, Jazz Pharmaceuticals plc From 02/13/24

NORTHAMPTON, MA / ACCESSWIRE / February 13, 2024 / Jazz Pharmaceuticals Originally published on LinkedIn Jazz Pharmaceuticals' Chief People Officer Heidi Manna recently appeared on an episode of the Future of HR Podcas t where she discussed our innovative work model, "Jazz Remix." Hear ...

2024-02-10 14:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

NORTHAMPTON, MA / ACCESSWIRE / February 9, 2024 / Jazz Pharmaceuticals By Chase Feiger, M.D. Originally Published by Forbes For a company to successfully create new and life-changing therapeutics for people, it must begin by establishing its own people-first and mission-driven culture. T...

2024-02-07 07:35:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech investing is not for impatient investors. So why is it attractive to some investors? Ernest Hemingway penned the line “gradually, then suddenly,” referring to how someone ...

2024-02-07 03:41:50 ET More on Jazz Pharmaceuticals Updated View On Jazz Pharmaceuticals' 2025 Goals Jazz Pharmaceuticals' Zanidatamab Promises Growth Amidst Market Undervaluation Jazz Pharma PTSD mid-stage trial fails to meet main goal, stock slips after hours ...

Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program PR Newswire Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in ad...

2024-02-06 10:04:54 ET Summary Zymeworks' share price is moving higher lately, led by an overall recovery of biotech stocks, and possibly by increased investor interest in the company’s emerging antibody-drug conjugate platform. The topline results from the phase 3 trial of...

2024-01-31 13:04:00 ET Summary ZYME's partners, JAZZ and BGNE, are potentially within a year of approval and launch of zanidatamab, a bispecific anti-HER2 antibody. The approval and launch of zanidatamab in multiple markets could generate significant milestones and royalty streams...

2024-01-29 15:17:00 ET Summary Jazz Pharmaceuticals is likely to fall short of its 2025 revenue goal of $5 billion unless it makes a bold M&A move. Despite this, the stock looks undervalued and has the potential to re-rate higher, driven by the growth of Xywav, Rylaze, and Epi...

2024-01-28 02:56:55 ET Summary Avadel Pharmaceuticals has made good progress with the launch of Lumryz, enrolling 1,900 patients and generating $19 million in Q4 net sales. Legal risks from competitor Jazz Pharmaceuticals remain a concern, with ongoing litigation and the potential...